|
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT Clinical research trials and The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT. The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT clinical trial. Participants frequently obtain the most expert healthcare available for their The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.
Details: Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52 weeks. PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV positivity. - CD4 count 100-300 cells/mm3. - Prior AZT therapy for 24 or more weeks and currently on AZT. Exclusion Criteria Patients with the following prior conditions are excluded: - History of intolerance to AZT. - History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: - Any prior antiretroviral therapy other than AZT. Required: - Concomitant AZT therapy. Required: - At least 24 weeks of prior AZT.
Total Enrollment: 325
Location and Contact Information:
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas, 75235
United States
Nicholaos Bellos
Dallas, Texas, 75246
United States
Central Texas Med Foundation
Austin, Texas, 78751
United States
Louisiana Cardiovascular Research Ctr
New Orleans, Louisiana, 70119
United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, 30308
United States
Duke Univ Med Ctr
Durham, North Carolina, 27710
United States
ViRx Inc
San Francisco, California, 94103
United States
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, 97210
United States
San Diego Community Research Group
San Diego, California, 92104
United States
Montreal Gen Hosp
Montreal, Quebec,
Canada
Milton S Hershey Med Ctr
Hershey, Pennsylvania, 17033
United States
Nassau County Med Ctr
East Meadow, New York, 11554
United States
Ottawa General Hospital
Ottawa, Ontario,
Canada
Boston City Hosp / FGH-1
Boston, Massachusetts, 02118
United States
Wisconsin Community - Based Research Consortium
Milwaukee, Wisconsin, 53202
United States
Saint Luke's - Roosevelt Hosp Ctr
New York City, New York, 10019
United States
Houston Clinical Research Network
Houston, Texas, 77006
United States
Chicago Ctr for Clinical Research
Chicago, Illinois, 60607
United States
Nalle Clinic
Charlotte, North Carolina, 28207
United States
Toronto Hosp
Toronto, Ontario,
Canada
Hosp Regional de Ponce - Area Vieja
Ponce, , 00731
Puerto Rico
Combat Group
Los Angeles, California, 90028
United States
Additional Information:
Study ID Numbers: 129C; NUCA 3002
Study Start Date:
Record last reviewed: May 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002436
Other Hiv Infections Studies:
1. A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination with Soluble Recombinant Envelope Vaccine (VaxSyn)
2. A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients with CD4 Cell Counts Less than 50 Cells/mm3 or 300-500 Cells/mm3
3. Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel with Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects with Acquired Immunodeficiency Syndrome (AIDS)
4. Tuberculosis in HIV Infected Patients in Uganda
5. Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected with HIV
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Durham Clinical Trials
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
|
|
|
|
|
|
|
|